Institute for Rare and Neglected Diseases Drug Discovery

Recent papers from Institute for Rare and Neglected Diseases Drug Discovery

1. Development of a Bioluminescent High-Throughput Screening Assay for Nicotinamide Mononucleotide Adenylyltransferase (NMNAT)SLAS DISCOVERY · 2019
2. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare DiseasesClinical Pharmacology & Therapeutics · 2016
3. Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African TrypanosomeACS Infectious Diseases · 2016
4. On the different experimental manifestations of two‐state ‘induced‐fit’ binding of drugs to their cellular targetsBritish Journal of Pharmacology · 2016
5. Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active SubstratesCurrent Drug Discovery Technologies · 2016
6. The Role of Binding Kinetics in GPCR Drug DiscoveryCurrent Topics in Medicinal Chemistry · 2015
7. Collaboration for rare disease drug discovery researchF1000Research · 2014
8. The Discovery of Medicines for Rare DiseasesFuture Medicinal Chemistry · 2014
9. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligandsBritish Journal of Pharmacology · 2014
10. The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class MedicinesSLAS DISCOVERY · 2013
11. Phenotypic vs. Target-Based Drug Discovery for First-in-Class MedicinesClinical Pharmacology & Therapeutics · 2013
12. Transcriptomic analysis of the woodchuck model of chronic hepatitis BHepatology · 2012